PeptiDream Inc (TYO: 4587) has appointed Dr Kiyofumi Kaneshiro to its management team, the Japanese biopharmaceutical company announced on Friday.
Dr Kaneshiro brings a wealth of experience, with his previous role seeing him serve as a partner and managing director at The Boston Consulting Group (BCG).
During his time at BCG, Dr Kaneshiro worked with clients in the pharmaceutical and medtech sectors and led corporate growth strategy development, M&A strategy development, new business launch and R&D productivity.
As executive vice president at PeptiDream, Dr Kaneshiro will work with president & CEO Dr Patrick C. Reid and executive VP Dr Keiichi Masuya to manage and direct all scientific, strategic and business efforts.
Discussing Dr Kaneshiro's appointment, Dr Reid said his range of abilities and experience would help guide PeptiDream toward its business and strategic objectives as the company enters the next phase of growth.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study